Product Description
Mechanisms of Action: 5-HT3 Antagonist,SSR Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: IXALTIS
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Urinary Incontinence|Enuresis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IXA-CSP-002 | P2 |
Completed |
Urinary Incontinence|Enuresis |
2019-05-30 |
|
| 2016-004307-30 | P2 |
Completed |
Urinary Incontinence |
2018-11-12 |